Efficacy of Starting Methotrexate Early in Chikungunya Arthritis

• Status: Completed
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single center, prospective, randomized controlled open label trial with a one sided cross over design to compare the efficacy of initiating Methotrexate(Mtx) in early post Chikungunya induced arthritis (4-12 weeks after onset) with Non Steroidal Anti inflammatory Drugs(NSAID) alone.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

1. Patients of confirmed CHIK-V infection as per WHO guidelines defined as atleast one of the following

1. Presence of viral ribonucleic acid in sera determined with RT -PCR in acute phase < 7 days of fever

2. Presence of virus specific IgM antibodies in serum

2. Persistent arthritis after 4 weeks of onset of fever and duration less than 12 weeks

3. Age more than 16 years

4. Patients willing to give informed consent

Exclusion Criteria:

1. Patients with mixed infection i.e. dengue.

2. Having a known rheumatological disease and currently taking treatment

3. Pregnant and breastfeeding women

4. Any contraindication to methotrexate